Literature DB >> 19002052

Elevated first trimester soluble fibrin polymer is associated with adverse pregnancy outcome in thrombophilic patients.

Michael J Paidas, De-Hui W Ku, Gabriele Urban, Nazli Hossain, Andrei Rebarber, Charles J Lockwood, Yale S Arkel.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19002052      PMCID： PMC3036561          DOI： 10.1097/MBC.0b013e32830ebb5c

Source DB:  PubMed          Journal:  Blood Coagul Fibrinolysis        ISSN： 0957-5235            Impact factor:   1.276


× No keyword cloud information.
  10 in total

1.  Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium.

Authors:  K Bremme; E Ostlund; I Almqvist; K Heinonen; M Blombäck
Journal:  Obstet Gynecol       Date:  1992-07       Impact factor: 7.661

2.  Pregnant patients with thrombophilia and subsequent adverse pregnancy outcomes have a decreased first trimester response to thrombomodulin in an activated partial thromboplastin time (APTT) system.

Authors:  M J Paidas; D-H W Ku; M-J Lee; C J Lockwood; Y S Arkel
Journal:  J Thromb Haemost       Date:  2004-05       Impact factor: 5.824

3.  Antiphospholipid antibody syndrome.

Authors:  M D Lockshin
Journal:  JAMA       Date:  1992-09-16       Impact factor: 56.272

4.  Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.

Authors:  S Eichinger; A Weltermann; K Philipp; E Hafner; A Kaider; E M Kittl; B Brenner; C Mannhalter; K Lechner; P A Kyrle
Journal:  Thromb Haemost       Date:  1999-10       Impact factor: 5.249

5.  Elevated first trimester maternal levels of soluble fibrin polymer are associated with lower birthweight in twin gestation.

Authors:  Gabriele Urban; De Hui Ku; Yale Arkel; Andrei Rebarber; Charles J Lockwood; Michael J Paidas
Journal:  Blood Coagul Fibrinolysis       Date:  2006-07       Impact factor: 1.276

6.  Prothrombin activation fragment (F1.2) is increased in pregnant patients with antiphospholipid antibodies.

Authors:  M Zangari; C J Lockwood; J Scher; J H Rand
Journal:  Thromb Res       Date:  1997-02-01       Impact factor: 3.944

7.  Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.

Authors:  T Bombeli; P Raddatz-Mueller; J Fehr
Journal:  Am J Obstet Gynecol       Date:  2001-02       Impact factor: 8.661

8.  Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium.

Authors:  A Gerhardt; R E Scharf; M W Beckmann; S Struve; H G Bender; M Pillny; W Sandmann; R B Zotz
Journal:  N Engl J Med       Date:  2000-02-10       Impact factor: 91.245

9.  The use of coagulation activation markers (soluble fibrin polymer, TpP, prothrombin fragment 1.2, thrombin-antithrombin, and D-dimer) in the assessment of hypercoagulability in patients with inherited and acquired prothrombotic disorders.

Authors:  Y S Arkel; M J Paidas; D H Ku
Journal:  Blood Coagul Fibrinolysis       Date:  2002-04       Impact factor: 1.276

Review 10.  Adverse pregnancy outcome, the uteroplacental interface, and preventive strategies.

Authors:  Nazli Hossain; Michael J Paidas
Journal:  Semin Perinatol       Date:  2007-08       Impact factor: 3.300
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.